monterey bio (“mtryu”) is a specialty purpose acquisition company (spac) with the goal of effecting a merger, asset acquisition, or similar business combination with business targets that are developing or enabling development of pre-commercial therapeutic candidates across a broad array of therapeutic areas, with an initial focus on oncology and immunology.
Company profile
Ticker
MTRY, MTRYU, MTRYW
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Monterey Bio Acquisition Corp
SEC CIK
IRS number
852204842
MTRY stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
19 Dec 23
8-K
Other Events
1 Dec 23
25-NSE
Exchange delisting
20 Nov 23
8-K
Other Events
7 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Oct 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
8-K
Entry into a Material Definitive Agreement
10 Jul 23
DEFA14A
Additional proxy soliciting materials
30 Jun 23
8-K
Other Events
30 Jun 23
Latest ownership filings
SC 13G/A
MMCAP International Inc. SPC
13 Feb 24
4
Change in insider ownership
11 Apr 23
3
Initial statement of insider ownership
11 Apr 23
SC 13D
GROSSMAN JONAS
27 Mar 23
4
JONAS GROSSMAN
13 Mar 23
4
Change in insider ownership
13 Mar 23
4
William McKeever
13 Mar 23
4
Sanjeev Satyal
13 Mar 23
4
Sandip I Patel
13 Mar 23
3
Chris D. Coleman
13 Mar 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 539.79 k | 539.79 k | 539.79 k | 539.79 k | 539.79 k | 539.79 k |
Cash burn (monthly) | (no burn) | (no burn) | 121.87 k | 169.31 k | 113.42 k | 81.76 k |
Cash used (since last report) | n/a | n/a | 1.17 mm | 1.63 mm | 1.09 mm | 786.45 k |
Cash remaining | n/a | n/a | -632.41 k | -1.09 mm | -551.11 k | -246.66 k |
Runway (months of cash) | n/a | n/a | -5.2 | -6.4 | -4.9 | -3.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 2 |
Closed positions | 7 |
Increased positions | 0 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 7.57 bn |
Total shares | 9.97 mm |
Total puts | 0.00 |
Total calls | 30.84 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Northstar Bio Ventures | 1.91 mm | $0.00 |
Grossman Jonas | 1.10 mm | $0.00 |
EHP Funds | 938.63 k | $26.94 mm |
MMCAP International Inc. SPC | 625.00 k | $17.94 mm |
Space Summit Capital | 600.00 k | $6.07 mm |
Periscope Capital | 531.20 k | $15.25 mm |
Shaolin Capital Management | 395.60 k | $11.00 k |
Boothbay Fund Management | 388.44 k | $4.33 bn |
Atw Spac Management | 384.99 k | $11.05 mm |
Polar Asset Management Partners | 384.81 k | $11.04 mm |